JACC Journals

05/16/2026

🚨 Risk prediction in primary prevention

In 79,497 Chinese adults without atherosclerotic cardiovascular disease, the Pooled Cohort Equations and China-PAR overestimated the 10-year risk, while PREVENT underestimated it

🔧 Recalibration to local data improved calibration and risk stratification. Learn more in :

05/15/2026

In this review, Dr. Parag Goyal et al. summarize current clinical strategies for predicting risk of transthyretin amyloid cardiomyopathy, highlight remaining evidence gaps, and discuss health system approaches for systematic screening.

AbstractTransthyretin amyloid cardiomyopathy (ATTR-CM) remains underdiagnosed relative to population estimates in at-risk populations. Efforts have identified clinical features that identify risk f...

05/15/2026

Last day to submit to !

Share your research on immunology, cancer, and shared pathways, biomarkers, immune-mediated injury, inflammation-driven cardiotoxicity, immunometabolism, and beyond.

Complete Your Submission: https://bit.ly/4tiv7aD

05/14/2026

Short-Term Air Pollution Can Be Deadly in High-Risk Hypertension 🌁

The sicker the patient, the more air quality matters. 🫁

In a nationwide study of >2.1 million deaths in China, mortality risk associated with air pollution increased progressively with hypertensive disease severity, with the highest risk observed among patients with cardiorenal failure. This suggests air pollution may act as an acute cardiovascular stressor and underscores the incorporation of environmental exposures in cardiovascular risk.

More in the new focus issue of : https://bit.ly/3PCSRbI

05/13/2026

📢 call for papers extended!

Focusing on the overlap of immunology, cancer, and shared pathways, biomarkers, immune-related cardiovascular injury, inflammation-driven cardiotoxicity, immunometabolism, and more.

Submit by May 15: https://bit.ly/4tiv7aD

05/13/2026

Single-pill low-dose triple therapy may be a smarter front door for hypertension care. In two phase III trials, amlodipine/losartan/chlorthalidone effectively controlled blood pressure, outperforming losartan and avoiding excess adverse events. Less inertia. More control. 💊

Learn more in : https://www.jacc.org/doi/10.1016/j.jacc.2025.12.028?utm_medium=social&utm_source=social_post&utm_campaign=social_post

05/12/2026

🆕 in JACC: This special issue highlights the latest in hypertension research, spanning global population trends, clinical trials, and real-world implementation.

It explores 🔑 relationships between blood pressure and outcomes such as diabetes, while evaluating pharmacologic and lifestyle-based treatment strategies. The issue also examines environmental and genetic contributors to hypertension, along with emerging approaches to blood pressure measurement and management across the lifespan.

We invite you to explore this collection of new evidence shaping the future of hypertension research and care: https://bit.ly/42qos3k

05/12/2026

ECMO flow up, filling pressures... unchanged?

ECMO boosts circulation, but crank up the flow and you’d expect LV afterload and filling pressures to rise.

Not so fast.

PAPO Flow showed PCWP stayed flat across flows. Cue the “models are wrong” narrative.

A new JACC letter flips it: those models were built on sicker, unstable patients, but PAPO Flow? Stable, post-initiation ECMO. Simulate that population and the model nails it, flat PCWP and all.

ECMO physiology isn’t broken, so don't ditch the models. Match them to the right patient.

Read more in a new issue of JACC: https://bit.ly/4nndLrW

05/12/2026

In this article, Dr. Po-Yen Hsu, and colleagues demonstrate that circulating mPIH1D1 levels serve as a biomarker of left ventricular ejection fraction reduction after anthracycline therapy.

Get the details: https://bit.ly/426N29e

05/11/2026

Recovery after MI isn’t only physical.

Cardiac anxiety remains an underrecognized barrier. This trial shows that targeting it with digital CBT can improve patient health status and outcomes.

Explore the full study in : https://bit.ly/4txFZ4L

05/11/2026

The ALLEVIATE-HF-1 & ALLEVIATE-HF-2 pilot studies collectively show that a no-implant interatrial shunt is feasible and safe, with patency to 12 months and a signal for sustained efficacy. Findings now being tested in the sham-controlled ALLAY-HF trial.

Learn more in : https://bit.ly/491itpe